Why Is Axis Capital (AXS) Up 9.5% Since Last Earnings Report?
It has been about a month since the last earnings report for
frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next
earnings release, or is
dive into how investors and analysts have reacted as of late, let's
take a quick look at its most recent earnings report in order to
get a better handle on the important drivers.
Estimates
AXIS Capital Holdings Limited AXS posted fourth-quarter 2023
operating income of
Consensus Estimate of a loss of
50.8% year over year.
The insurer's results reflected higher premiums written, net
investment income and increased underwriting income.
Quarterly Operational Update
Total operating revenues of
Consensus Estimate by 2.7%. The top line however declined 2.1% year
over year on lower premiums earned.
Net premiums written decreased 2% to
attributable to a 51% decline in the Reinsurance segment, partially
offset by a 9% increase in the Insurance segment. Our estimate was
Net investment income increased 27.2% year over year to
million
maturities portfolio due to increased yields. Our estimate was
Total expenses in the quarter under review increased 21.8%
year over year to
expenses. Our estimate for the same was also
Catastrophe and weather-related losses and net of reinsurance
were
million
against the year-ago income of
The combined ratio deteriorated 3050 basis points (bps) to
124.6. The Zacks Consensus Estimate was pegged at 115, while our
estimate was 131.
Segment Results
Insurance: Gross premiums written improved 7.7%
year over year to
business, with the exception of professional lines, which decreased
in the quarter, principally due to the unattractive pricing
environment for
Our estimate for gross premiums was
premiums earned increased 9.4% year over year to
Our estimate was
Underwriting loss was
The Zacks Consensus Estimate for combined ratio was pegged at 81.
Reinsurance: Gross premiums written decreased
30.2% year over year to
level of positive premium adjustments in the quarter compared with
the prior year and the timing of renewals of significant contracts.
Our estimate was
Net premiums earned decreased 51.2% year over year to
million
Underwriting loss was
income of
year over year to 162.8. The Zacks Consensus Estimate for combined
ratio was pegged at 135.
Full-Year Highlights
Operating income of
Revenues of
Net premiums written decreased 2% to
Underwriting income of
over year. Combined ratio deteriorated 410 basis points.
Financial Update
billion
Debt was
2022-end level.
Book value per share increased 15.1% from 2022 end to
as of
reported in accumulated other comprehensive income (loss),
partially offset by net loss for the period, and common share
dividends declared.
Annualized operating return on average common equity was 11%,
which contracted 10 bps year over year.
Capital Deployment
through
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in
estimates revision.
VGM Scores
Currently,
however its Momentum Score is doing a bit better with a B. Charting
a somewhat similar path, the stock was allocated a grade of A on
the value side, putting it in the top 20% for this investment
strategy.
Overall, the stock has an aggregate VGM Score of
aren't focused on one strategy, this score is the one you should be
interested in.
Outlook
Estimates have been broadly trending upward for the stock, and
the magnitude of these revisions indicates a downward shift. It
comes with little surprise
Buy). We expect an above average return from the stock in the next
few months.
Performance of an Industry Player
Casualty industry. Another stock from the same industry,
Berkley
month has passed since the company reported results for the quarter
ended
reported quarter, representing a year-over-year change of +9.4%.
EPS of
ago.
For the current quarter,
earnings of
year-ago quarter. The Zacks Consensus Estimate has changed +0.8%
over the last 30 days.
The overall direction and magnitude of estimate revisions
translate into a Zacks Rank #2 (Buy) for
stock has a VGM Score of A.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5
favorite to skyrocket +100% or more in months to come. From those
5, Director of Research
explosive upside of all.
It's a little-known chemical company that's up 65% over last
year, yet still dirt cheap. With unrelenting demand, soaring 2022
earnings estimates, and
retail investors could jump in at any time.
This company could rival or surpass other recent
Set to Double like
little more than 9 months and NVIDIA which boomed +175.9% in one
year.
Free:
See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report



Markel Group (MKL) Up 7% Since Last Earnings Report: Can It Continue?
Why Is MetLife (MET) Up 6.7% Since Last Earnings Report?
Advisor News
- The modern advisor: Merging income, insurance, and investments
- Financial shocks, caregiving gaps and inflation pressures persist
- Americans unprepared for increased longevity
- More investors will seek comprehensive financial planning
- Midlife planning for women: why it matters and how advisors should adapt
More Advisor NewsAnnuity News
- LIMRA: Annuity sales notch 10th consecutive $100B+ quarter
- AIG to sell remaining shares in Corebridge Financial
- Corebridge Financial, Equitable Holdings post Q1 earnings as merger looms
- AM Best Assigns Credit Ratings to Calix Re Limited
- Transamerica introduces new RILA with optional income features
More Annuity NewsHealth/Employee Benefits News
- Hospital, clinics hurting as fewer Tri-Cities patients have health care coverage
- Reports on Insurance from State University of New York (SUNY) Albany Provide New Insights (Effects of National Insurance Reforms and State Medicaid Expansions Under the Affordable Care Act on Insurance Coverage Among American Indian and Alaska …): Insurance
- Findings from Kristi Martin et al Has Provided New Information about Managed Care and Specialty Pharmacy (Assessment of IPAY 2027 Medicare drug price negotiation maximum fair prices with prices in most-favored nation reference countries): Drugs and Therapies – Managed Care and Specialty Pharmacy
- Data on Hypertension Discussed by Denise Wolff and Colleagues (AMCP Market Insights: Getting to the heart of hard-to-control hypertension in managed care): Cardiovascular Diseases and Conditions – Hypertension
- Democratic candidates revive single-payer promise as California's healthcare system faces strain
More Health/Employee Benefits NewsLife Insurance News
- AM Best Assigns Credit Ratings to Tokio Marine Newa Insurance Co., Ltd.
- Earnings roundup: Prudential works to save ‘unique’ Japanese market
- How life insurance became a living-benefits strategy
- Financial Focus : Keep your beneficiary choices up to date
- Equitable-Corebridge merger casts shadow over life insurance earnings
More Life Insurance News